MAPT and Alzheimer disease: CSF Aβ42 levels were significantly lower and t-tau higher in Alzheimer’s disease compared with subjective cognitive decline and mild cognitive impairment participants (P < 0.0001 for both comparisons), while p-tau levels did not differ after age correction (P = 0.108).